

Qian Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2788689/publications.pdf>

Version: 2024-02-01

44
papers

44
citations

2257263

3
h-index

1719596

7
g-index

44
all docs

44
docs citations

44
times ranked

53
citing authors

#	ARTICLE	IF	CITATIONS
1	Preconditioning Using Naltrindole or its Analogues Exerts Robust Infarct-Sparing Effects in Rat Myocardial Ischemia/Reperfusion. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
2	Myristoylated Protein Kinase C Beta II Inhibitor Attenuates Renal Injury in Mice Subjected to Severe Bilateral Ischemia-Reperfusion. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
3	Myristic Acid-Trans-Activator of Transcription Dual Conjugation Improves Intracellular Delivery of Protein Kinase C Beta II Peptide Inhibitor Cargo in Isolated Rat Polymorphonuclear Leukocytes. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
4	Naltrindole Pretreatment Exhibits Robust Cardioprotection in an Acute In Vivo Model of Ischemia/Reperfusion. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
5	Naltrindole Exhibits Robust Cardioprotection in Myocardial Ischemia Reperfusion Injury. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
6	Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 49.	1.0	14
7	Abstract P500: Naltrindole And Naltrindole Derivatives Exhibit Potent Cardioprotection In Myocardial Ischemia Reperfusion Injury. <i>Circulation Research</i> , 2021, 129, .	2.0	0
8	Abstract P509: Novel Protein Kinase C Epsilon Inhibitor Attenuates Uncoupled Endothelial Nitric Oxide Synthase And Vascular Endothelial Dysfunction. <i>Circulation Research</i> , 2021, 129, .	2.0	0
9	Myristoylation of Novel Protein Kinase C Beta II Peptide Inhibitor is Required for the Attenuation of Phorbol 12-myristate 13-acetate-induced Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
10	Abstract 445: Myristoylated Protein Kinase C Beta II Peptide Inhibitor Attenuates Hypoxia-Reoxygenation Injury in Human Umbilical Vein Endothelial Cells. <i>Circulation Research</i> , 2020, 127, .	2.0	0
11	Abstract 447: Myristoylation of Protein Kinase C Beta II Peptide Inhibitor Facilitates Rapid Attenuation of Phorbol 12-myristate 13-acetate in Activated Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes. <i>Circulation Research</i> , 2020, 127, .	2.0	0
12	Protein Kinase C Beta II Peptide Inhibitor Elicits Robust Effects on Attenuating Myocardial Ischemia/Reperfusion Injury. <i>FASEB Journal</i> , 2019, 33, 690.6.	0.2	0
13	Protein Kinase C Beta II Peptide Modulation of Superoxide Release in Rat Polymorphonuclear Leukocytes. <i>FASEB Journal</i> , 2019, 33, 836.5.	0.2	0
14	The Effects of Metformin, Aminoguanidine, and Pyridoxamine on Methylglyoxal Induced Cardiac Myocytes Injury. <i>FASEB Journal</i> , 2019, 33, 514.6.	0.2	0
15	Modulation of Nitric Oxide Release in Human Umbilical Vein Endothelial Cells by Myristoylated-epsilonPKC Epsilon Activator/Inhibitor Peptides. <i>FASEB Journal</i> , 2018, 32, 902.19.	0.2	0
16	The Role of Autophagy During Myocardial Ischemia/Reperfusion Injury. <i>FASEB Journal</i> , 2018, 32, 717.21.	0.2	0
17	Comparing the Efficacy of Pharmacological Preconditioning with Myristic Acid-conjugated, TAT-conjugated and Native Protein Kinase C Epsilon Peptide Activator in Myocardial Ischemia/Reperfusion (MI/R) Models. <i>FASEB Journal</i> , 2018, 32, .	0.2	0
18	Cardioprotective Effects by a Novel Opioid Peptide in Myocardial Ischemia/Reperfusion Injury. <i>FASEB Journal</i> , 2018, 32, 717.23.	0.2	0

#	ARTICLE	IF	CITATIONS
19	The Effects of Metformin on Methylglyoxal-induced cardiomyocytes cell damage. FASEB Journal, 2018, 32, 719.11.	0.2	0
20	Protein Kinase C Epsilon Peptide Inhibitor Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury. FASEB Journal, 2017, 31, 846.17.	0.2	2
21	Effects of NOX1 on Real-time Blood Nitric Oxide and Hydrogen Peroxide in Acute Hyperglycemia. FASEB Journal, 2016, 30, 734.10.	0.2	0
22	The Cardioprotective Effects of the Mitochondrial Fission Inhibitor, P110, on Myocardial Ischemia/Reperfusion (MI/R) Injury. FASEB Journal, 2015, 29, 954.7.	0.2	0
23	The Cardioprotective Effects of a NOX1 Inhibitor, ML171, on Myocardial Ischemia/Reperfusion (I/R) injury. FASEB Journal, 2015, 29, 635.3.	0.2	0
24	Mdivi-1, a Novel Mitochondrial Fission Inhibitor, Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion (MI/R) Injury. FASEB Journal, 2015, 29, 1049.1.	0.2	2
25	Inhibition of long chain fatty acyl-CoA synthetase (ACSL) and ischemia reperfusion injury. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1057-1061.	1.0	7
26	Apocynin exerts dose-dependent cardioprotective effects by attenuating reactive oxygen species (ROS) in ischemia/reperfusion (I/R). FASEB Journal, 2013, 27, 1191.1.	0.2	0
27	TRIACSIN C, A FATTY ACYL COA SYNTHETASE (FACS) INHIBITOR, IMPROVES CARDIAC PERFORMANCE FOLLOWING GLOBAL ISCHEMIA. FASEB Journal, 2012, 26, 1136.18.	0.2	4
28	The effects of modulating eNOS activity and coupling on leukocyte-endothelial interactions in rat mesenteric postcapillary venules. FASEB Journal, 2012, 26, 680.12.	0.2	0
29	Tetrahydrobiopterin (BH4) attenuates extracorporeal shock wave lithotripsy (ESWL) induced blood nitric oxide (NO) level reduction in the renal vein. FASEB Journal, 2012, 26, 1137.5.	0.2	0
30	Effects of NADPH oxidase inhibitor apocynin on real-time blood hydrogen peroxide release in femoral artery/vein ischemia and reperfusion. FASEB Journal, 2012, 26, 678.8.	0.2	0
31	Apocynin exerts cardioprotection in ischemia/reperfusion (I/R) by inhibiting superoxide release from NADPH oxidase. FASEB Journal, 2012, 26, 1136.16.	0.2	0
32	The Role of Tetrahydrobiopterin and Dihydrobiopterin in Ischemia/Reperfusion Injury When Given at Reperfusion. Advances in Pharmacological Sciences, 2010, 2010, 1-11.	3.7	12
33	Inhibition of protein kinase C beta II attenuates local hyperglycemia-induced leukocyte-endothelial interactions. FASEB Journal, 2010, 24, 590.12.	0.2	0
34	The roles of protein kinase C (PKC) epsilon and tetrahydrobiopterin (BH 4)/dihydrobiopterin (BH 2) related to endothelial nitric oxide synthase (eNOS) coupling/uncoupling in ischemia/reperfusion (I/R). FASEB Journal, 2010, 24, 591.12.	0.2	0
35	The attenuation of leukocyte-endothelial interactions by a unique broad-spectrum protein kinase C inhibitor (GÅ¶ 6983) in rat mesenteric postcapillary venules. FASEB Journal, 2009, 23, 762.7.	0.2	0
36	Protein kinase C beta II inhibitor attenuates leukocyte-endothelial interactions during acute endothelial dysfunction. FASEB Journal, 2009, 23, 762.9.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Real time measurement of hydrogen peroxide (H ₂ O ₂) or nitric oxide (NO) in femoral ischemia/reperfusion (I/R): Effects of protein kinase C (PKC) epsilon activator (Îµ+) or inhibitor (Îµâ€) combined with tetrahydrobiopterin (BH ₄) or dihydrobiopterin (BH ₂). FASEB Journal, 2009, 23, 617.19.	0.2	1
38	Mechanisms related to endothelial nitric oxide synthase (eNOS) uncoupling in myocardial ischemia/reperfusion (MI/R). FASEB Journal, 2009, 23, 793.13.	0.2	0
39	Real time measurement of hydrogen peroxide (H ₂ O ₂) and nitric oxide (NO) release in the renal vein: The effects of Protein Kinase C beta II inhibitor (PKC Î²â€) on rat kidneys exposed to extracorporeal shock wave lithotripsy (ESWL). FASEB Journal, 2008, 22, 1160.8.	0.2	1
40	The mechanisms related to the cardioprotective effects of protein kinase C epsilon (PKC Îµâ€) peptide inhibitor in ischemia/reperfusion (I/R) injury when given at reperfusion. FASEB Journal, 2008, 22, 730.27.	0.2	0
41	Real time measurement of hydrogen peroxide (H ₂ O ₂) and nitric oxide (NO) release in femoral vein ischemia and reperfusion (I/R): The effects of tetrahydrobiopterin (BH ₄)/dihydrobiopterin (BH ₂) and the effects of Protein Kinase C (PKC) epsilon activation (Îµ+)/inhibition (Îµâ€). FASEB Journal, 2008, 22, 730.1.	0.2	0
42	The combination of protein kinase C epsilon activator (PKC Îµ+) and tetrahydrobiopterin (BH ₄) exerts cardioprotective effects in ischemia/reperfusion injury (I/R) when given during reperfusion. FASEB Journal, 2008, 22, 730.22.	0.2	0
43	Tetrahydrobiopterin (BH ₄) exerts cardioprotective effects in ischemia/reperfusion injury when given at reperfusion. FASEB Journal, 2007, 21, A1145.	0.2	0
44	Tetrahydrobiopterin (BH ₄) attenuates neutrophil adhesion/transmigration in myocardial ischemia/reperfusion injury. FASEB Journal, 2007, 21, A1145.	0.2	1